We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 16, 2022

Sintilimab Plus Bevacizumab Biosimilar IBI305 and Chemotherapy for EGFR-Mutated Non-Squamous NSCLC After Progression on EGFR-TKI Therapy

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Lancet Oncol 2022 Jul 28;[EPub Ahead of Print], S Lu, L Wu, H Jian, Y Chen, Q Wang, J Fang, Z Wang, Y Hu, M Sun, L Han, L Miao, C Ding, J Cui, B Li, Y Pan, X Li, F Ye, A Liu, K Wang, S Cang, H Zhou, X Sun, D Ferry, Y Lin, S Wang, W Zhang, C Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading